Jaguar Health Secures Australian Patent for Crofelemer in Treating Short Bowel Syndrome and Related Disorders

Reuters11-24
Jaguar Health Secures Australian Patent for Crofelemer in Treating Short Bowel Syndrome and Related Disorders

Jaguar Health Inc. announced that the Australian Patent Office has issued a new patent to its family company, Napo Pharmaceuticals, for methods of treating short bowel syndrome $(SBS)$, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal in patients using an inhibitor of chloride-ion transport such as crofelemer. The company stated that this new patent expands international intellectual property protection for crofelemer's development in short bowel syndrome with intestinal failure and supports its strategy to advance crofelemer in rare pediatric intestinal failure disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1106126) on November 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment